The Aquaculture Vaccines Market Size is valued at USD 477.1 Million in 2023 and is predicted to reach 1003.7 Million by the year 2034 at a 7.5% CAGR during the forecast period for 2024-2034.
Vaccination creates or enhances immunity against a particular illness or group of illnesses. There is always a possibility of pathogenic outbreaks in aquaculture methods, impacting the farm's output. Vaccines for aquaculture are used to shield the fish from any infection. Increased demand for food products made from aquatic animals, such as oil, protein powders, caviar, and meat, as well as the rate of disease progression in marine animals, would restrain the growth of the aquaculture vaccines market. Over the forecast period, there is expected to be a rise in demand for commercial aquaculture vaccines due to the increased prevalence of bacterial diseases among aquatic species. The aquaculture vaccine market has also expanded due to rising global demand for and production of aquatic species.
However, the aquaculture vaccinations business has suffered due to the COVID-19 epidemic. Additionally, it's anticipated that short-term market weakness would result from growing knowledge of the risks associated with animal-to-human virus transmission. Moreover, complicated vaccine production processes, high vaccination costs, and strict regulatory requirements for aquaculture vaccine approval would restrain the market's expansion.
The Aquaculture Vaccines market is segmented on the vaccine type, application, route of administration and species. Based on the vaccine type, the market is segmented into Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine and Others. Based on application, the Aquaculture Vaccines are segmented into Bacterial Infection, Viral Infections, Combined Bacterial and Viral Infections and Others. Based on route of administration, the market is segmented into Immersion Vaccines, Injection Vaccines and Oral Vaccines. Based on species, the market is segmented into Salmon, Seabass and Seabream, Tilapia, Trout, Turbo and Carp.
Inactivated vaccines dominated the market for vaccinations used in aquaculture. Large quantities of the disease-causing microorganisms are fermented to create inactivated bacterial and viral vaccines. Then, inactivating chemicals like formalin are used to eliminate all the germs. These inactivated organisms have their basic structure, original antigen properties, and form, which causes an immune response. The recombinant vaccines market is projected to expand significantly. Recombinant vaccines can imitate naturally occurring illnesses and induce a potent immune response in inoculated fish. Recombinant vaccines are also simpler to manufacture on a large-scale, commercial basis.
Injection vaccines dominated the market share for aquaculture vaccines. Injection vaccinations allow for the direct induction of a systemic immune response by delivering antigens directly into a bodily cavity or muscle. Injection vaccines' superior capacity to cure various bacterial and viral infectious diseases compared to other routes of administration is thus expected to boost industry statistics.
The European Aquaculture Vaccines market is expected to register the highest market share in revenue in the near future. The main drivers propelling this regional market include Norway's position as the region's largest salmon exporter, supportive government and business sector initiatives, growing public concern about the prevalence of antibiotic resistance, and the existence of significant companies. The Norwegian Medicines Agency has specific guidelines and recommendations for autogenous vaccination applications. Additionally, autogenous vaccinations should only be used when commercial vaccines are either not accessible or do not provide adequate protection. In addition, Asia Pacific is projected to expand in the global Aquaculture Vaccines market because of growing demand, a thriving aquaculture industry, encouraging government initiatives, adequate water resources in many regions, and a drive toward sustainable aquaculture, among other factors. Several aquatic species, including tilapia, are abundant in this area.
| Report Attribute | Specifications |
| Market size value in 2023 | USD 477.1Million |
| Revenue forecast in 2034 | USD 1003.7 Million |
| Growth rate CAGR | CAGR of 7.5% from 2024 to 2034 |
| Quantitative units | Representation of revenue in US$ Million and CAGR from 2024 to 2034 |
| Historic Year | 2021 to 2023 |
| Forecast Year | 2024-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | Vaccine type, Route of Administration, Species, Application |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Pharmaq AS (Zoetis, LLC) (Norway), Merck Animal Health (Merck & Co., Inc.) (USA), KoVax Ltd. (Part of Phibro Animal Health) (Israel), Hipra (Spain), Tecnovax SA (Argentina), Veterquimica S.A. (Chile), Nisseiken Co. Ltd. (Japan), Virbac S.A. (France), Elanco (USA) and Kyoritsuseiyaku Corporation (Japan). |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Vaccine Type-
By Application-
By Route of Administration-
By Species-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Aquaculture Vaccines Market Snapshot
Chapter 4. Global Aquaculture Vaccines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Aquaculture Vaccines Market Penetration & Growth Prospect Mapping (US$ Mn),
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Aquaculture Vaccines Market Industry Trends
Chapter 5. Aquaculture Vaccines Market Segmentation 1: By Vaccine Type, Estimates & Trend Analysis
5.1. Market Share by Vaccine Type, 2023 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vaccine Type:
5.2.1. Inactivated Vaccine
5.2.2. Attenuated Live Vaccine
5.2.3. Others
Chapter 6. Aquaculture Vaccines Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Bacterial Infection
6.2.2. Viral Infections,
6.2.3. Others - Combined Bacterial and Viral Infections, parasitic
Chapter 7. Aquaculture Vaccines Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
7.2.1. Immersion Vaccines
7.2.2. Injection Vaccines
7.2.3. Oral Vaccines
Chapter 8. Aquaculture Vaccines Market Segmentation 4: By Species, Estimates & Trend Analysis
8.1. Market Share by Species, 2023 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Species:
8.2.1. Cold Water
8.2.1.1. Salmon
8.2.1.2. Trout
8.2.1.3. Turbot
8.2.1.4. Others
8.2.2. Hot Water
8.2.2.1. Tilapia
8.2.2.2. Seabass and Seabream
8.2.2.3. Others
Chapter 9. Aquaculture Vaccines Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Aquaculture Vaccines Market, Regional Snapshot 2023 & 2034
9.2. North America
9.2.1. North America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2024-2034
9.2.3. North America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2034
9.2.4. North America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2034
9.2.5. North America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Species, 2024-2034
9.3. Europe
9.3.1. Europe Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
9.3.1.1. Norway
9.3.1.2. Greece
9.3.1.3. Spain
9.3.1.4. Russia
9.3.1.5. UK
9.3.1.6. Rest of Europe
9.3.2. Europe Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2024-2034
9.3.3. Europe Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2034
9.3.4. Europe Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2034
9.3.5. Europe Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Species, 2024-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
9.4.1.1. China
9.4.1.2. Indonesia
9.4.1.3. Vietnam
9.4.1.4. india
9.4.1.5. Bangladesh
9.4.1.6. Phillipines
9.4.1.7. Rest of Asia Pacific
9.4.2. Asia Pacific Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2024-2034
9.4.3. Asia Pacific Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2034
9.4.4. Asia Pacific Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2034
9.4.5. Asia Pacific Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Species, 2024-2034
9.5. Latin America
9.5.1. Latin America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
9.5.1.1. Chile
9.5.1.2. Brazil
9.5.1.3. Mexico
9.5.1.4. Ecuador
9.5.1.5. Rest of Latin America
9.5.2. Latin America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2024-2034
9.5.3. Latin America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2034
9.5.4. Latin America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2034
9.5.5. Latin America Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Species, 2024-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
9.6.1.1. Egypt
9.6.1.2. Turkey
9.6.1.3. Iran
9.6.1.4. GCC countries
9.6.1.5. Rest of Middle East and Africa
9.6.2. Middle East & Africa Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2024-2034
9.6.3. Middle East & Africa Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2034
9.6.4. Middle East & Africa Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2034
9.6.5. Middle East & Africa Aquaculture Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Species, 2024-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Pharmaq AS (Zoetis, LLC)
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Merck Animal Health (Merck & Co., Inc.)
10.2.3. KoVax Ltd. (Part of Phibro Animal Health)
10.2.4. Hipra
10.2.5. Tecnovax SA
10.2.6. Veterquimica S.A.
10.2.7. Nisseiken Co. Ltd.
10.2.8. Virbac S.A.
10.2.9. Elanco
10.2.10. Kyoritsuseiyaku Corporation
10.2.11. Vaxxinova International BV
10.2.12. KBNP
10.2.13. Kemin Industries, Inc.
10.2.14. Kyoto Biken Laboratories, Inc.
10.2.15. CAVAC
10.2.16. Other Prominent Players